Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.
Open | $69.00 |
Close | $69.56 |
Volume / Avg. | 467.17K / 1.30M |
Day Range | 68.16 - 69.72 |
52 Wk Range | 45.50 - 84.89 |
Market Cap | $7.34B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 49 |
Short Interest | 4.05% |
Days to Cover | 6.38 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Intra-Cellular Therapies (NASDAQ:ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).
There is no analysis for Intra-Cellular Therapies.
Intra-Cellular Therapies has a consensus price target of $88.31.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $69.56 last updated July 5, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q2 earnings are confirmed for Thursday, August 1, 2024.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.